Registered title, quoted from ClinicalTrials.gov
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 4 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 5
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07061535, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) according to Veterans Administration Lung Study Group criteria;
Inclusion criterion 2
Age ≥18 years, ECOG performance status 0-1;
Inclusion criterion 1
Creatinine clearance rate < 60 mL/min (cisplatin) or < 45 mL/min (carboplatin)
Exclusion criterion 16
Greater than or equal to 1 measurable lesion exists according to RECIST v1.1;
Inclusion criterion 4
Active hepatitis B virus (HBV)/ hepatitis C virus (HCV)/ human immunodeficiency virus (HIV) infection;
Exclusion criterion 8
Pregnancy or lactation;
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07061535, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Key Inclusion Criteria:
- Age ≥18 years, ECOG performance status 0-1;
- Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) according to Veterans Administration Lung Study Group criteria;
- Previously not receiving systemic treatment for ES-SCLC;
- Greater than or equal to 1 measurable lesion exists according to RECIST v1.1;
- Expected survival >= 12 weeks;
- Adequate organ system functions (no blood transfusion or component blood use within 14 days before testing).
Key Exclusion Criteria:
- Previously receiving systemic anti-tumor therapy for ES-SCLC;
- Combined SCLC (mixed SCLC and NSCLC histological types) or transformed SCLC confirmed by histological or cytological examination;
- Receiving other investigational drugs or participated in other interventional clinical studies within 4 weeks before signing the informed consent form;
- Receiving systemic immunostimulant treatment within 4 weeks before enrollment;
- Active central nervous system (CNS) metastases (asymptomatic patients with stable lesions allowed);
- Severe cardiovascular disease;
- Severe chronic/active infections requiring systemic antibacterial, antifungal or antiviral treatment within 2 weeks before enrollment;
- Active hepatitis B virus (HBV)/ hepatitis C virus (HCV)/ human immunodeficiency virus (HIV) infection;
- Active autoimmune diseases, a history of interstitial lung disease, or other uncontrolled systemic diseases;
- Pregnancy or lactation;
- Having a disease that requires systemic corticosteroids or other immunosuppressants to be treated within ≤14 days before enrollment;
- Requiring at least monthly or more frequent drainage of pleural and/or pericardial or peritoneal effusion;
- Using attenuated live vaccines, or planned to receive attenuated live vaccines within 28 days before enrollment;
- Known to be allergic to Sintilimab or Tafolecimab or its excipients, having a history of severe allergic reaction to any monoclonal antibody, or having a history of allergy to cisplatin, carboplatin or etoposide;
- Toxicity caused by previous anti-cancer treatment has not recovered to baseline or stable state at the time of enrollment;
- Creatinine clearance rate < 60 mL/min (cisplatin) or < 45 mL/min (carboplatin)
- Uncontrolled or symptomatic hypercalcemia.
Quoted from ClinicalTrials.gov, NCT07061535, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07061535, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.